Veronique Ouellet

Summary

Country: Canada

Publications

  1. Ouellet V, Zietarska M, Portelance L, Lafontaine J, Madore J, Puiffe M, et al. Characterization of three new serous epithelial ovarian cancer cell lines. BMC Cancer. 2008;8:152 pubmed publisher
    ..This is the first report of the establishment of matched EOC cell lines derived from both solid tumor and ascites of the same patient. ..
  2. Ouellet V, Ling T, Normandin K, Madore J, Lussier C, Barrès V, et al. Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors. BMC Cancer. 2008;8:346 pubmed publisher
    ..02) or non-invasive (p = 0.01) implants compared to the LMP associated with invasive implants. This study represents an extensive analyse of the benign and highly differentiated ovarian disease from an immunohistochemical perspective. ..

Detail Information

Publications2

  1. Ouellet V, Zietarska M, Portelance L, Lafontaine J, Madore J, Puiffe M, et al. Characterization of three new serous epithelial ovarian cancer cell lines. BMC Cancer. 2008;8:152 pubmed publisher
    ..This is the first report of the establishment of matched EOC cell lines derived from both solid tumor and ascites of the same patient. ..
  2. Ouellet V, Ling T, Normandin K, Madore J, Lussier C, Barrès V, et al. Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors. BMC Cancer. 2008;8:346 pubmed publisher
    ..02) or non-invasive (p = 0.01) implants compared to the LMP associated with invasive implants. This study represents an extensive analyse of the benign and highly differentiated ovarian disease from an immunohistochemical perspective. ..